Louisville-based said
has exercised its option to license GI-6207, one of its cancer treatments, for $1.9 million.
This is the second time Celgene has chosen to license one of GlobeImmune’s products.
In 2009, in exchange for the exclusive right to market all of GlobeImmune’s experimental cancer therapies, more for meeting development, regulatory and sales goals. Summit, N.J.-based Celgene, a global biopharmaceutical company that manufactures drug therapies for cancer and inflammatory disorders, wanted to expand its lineup of cancer drugs beyond thalidomide-derived therapies for multiple myeloma.
GlobeImmune, which was founded in 1995, is a biopharmaceutical company that focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary
GI-6207 is in Phase 2 clinical trials by the National Cancer Institute that will review the product’s effectiveness in treating medullary thyroid cancer.
Currently, there are two drugs on the market that have been approved for the treatment of metastatic medullary thyroid cancer.
With more than 62,000 new cases estimated in 2015, thyroid cancer is the most common types of endocrine cancer in the U.S. Medullary tumors are the third most common of all thyroid cancers, making up 3 percent of the cases.
last year in its initial public offering.
Tierra Smith: 303-954-1046, tsmith@denverpost.com or twitter.com/ByTierraSmith
